This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-shhttp://sh.dbpedia.org/resource/
dcthttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n17https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n21http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
dbpedia-srhttp://sr.dbpedia.org/resource/
n16http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Symplocamide_A
rdf:type
yago:ProteaseInhibitor104013993 yago:Toxin115034074 yago:Poison115032376 yago:Medicine103740161 owl:Thing yago:Agent114778436 yago:Matter100020827 yago:WikicatBacterialToxins yago:WikicatProteaseInhibitors yago:Substance100020090 wikidata:Q11173 yago:BacterialToxin115034939 dbo:ChemicalCompound dbo:ChemicalSubstance yago:Drug103247620 yago:CausalAgent100007347 n21:ChemicalObject yago:Antiviral102725367 yago:PhysicalEntity100001930
rdfs:label
Symplocamide A
rdfs:comment
Symplocamide A is a newly discovered (2008) 3-amino-6-hydroxy-2-piperidone (Ahp) cyclodepsipeptide that has been isolated from a marine cyanobacteria in Papua New Guinea, which has only been identified at the genus level (Symploca). Cyanobacteria, both freshwater and marine, are known as producers of diverse protease inhibitors that may be used to treat diseases, such as HIV, and some forms of cancer. Research on symplocamide A has shown that it is a strong serine protease inhibitor and has a high level of cytotoxicity to cancer cells when used in vitro. As of the time of this writing, its use as a treatment on human participants has not been done and future study will have to be done before any human testing can be commenced.
foaf:name
Symplocamide A
dbp:name
Symplocamide A
foaf:depiction
n16:Symplocamide_A.svg
dct:subject
dbc:Depsipeptides dbc:Macrocycles dbc:Bacterial_toxins dbc:Protease_inhibitors
dbo:wikiPageID
31725673
dbo:wikiPageRevisionID
1038708722
dbo:wikiPageWikiLink
dbr:Protease_inhibitor_(pharmacology) dbc:Depsipeptides dbr:Neuroblastoma dbr:HIV dbr:Cyanobacteria dbr:Cytotoxin dbr:Nuclear_magnetic_resonance dbr:Lung_cancer dbc:Macrocycles dbr:Cyclodepsipeptide dbr:Serine_protease_inhibitor dbr:Papua_New_Guinea dbc:Bacterial_toxins dbc:Protease_inhibitors
owl:sameAs
yago-res:Symplocamide_A n17:4vNT6 dbpedia-sr:Simplokamid_A freebase:m.0gttt6g dbpedia-sh:Simplokamid_A wikidata:Q7661858
dbp:wikiPageUsesTemplate
dbt:Chemspidercite dbt:Cascite dbt:Chembox_Hazards dbt:Chembox_Identifiers dbt:Chembox dbt:Chembox_Properties dbt:Reflist
dbo:thumbnail
n16:Symplocamide_A.svg?width=300
dbp:imagefile
Symplocamide A.svg
dbp:imagename
Symplocamide A
dbp:imagesize
200
dbp:iupacname
N1-[-5--2-[-butan-2-yl]-15-[3-propyl]-21-hydroxy-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-8--10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docos-12-yl]-N2-butanoyl-L-glutamamide
dbo:abstract
Symplocamide A is a newly discovered (2008) 3-amino-6-hydroxy-2-piperidone (Ahp) cyclodepsipeptide that has been isolated from a marine cyanobacteria in Papua New Guinea, which has only been identified at the genus level (Symploca). Cyanobacteria, both freshwater and marine, are known as producers of diverse protease inhibitors that may be used to treat diseases, such as HIV, and some forms of cancer. Research on symplocamide A has shown that it is a strong serine protease inhibitor and has a high level of cytotoxicity to cancer cells when used in vitro. As of the time of this writing, its use as a treatment on human participants has not been done and future study will have to be done before any human testing can be commenced.
prov:wasDerivedFrom
wikipedia-en:Symplocamide_A?oldid=1038708722&ns=0
dbo:wikiPageLength
4950
dbo:iupacName
N1-[(2S,5S,8S,11R,12S,15S,18S,21R)-5-(3-bromo-4-methoxybenzyl)-2-[(2S)-butan-2-yl]-15-[3-(carbamoylamino)propyl]-21-hydroxy-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-8-(propan-2-yl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docos-12-yl]-N2-butanoyl-L-glutamamide
foaf:isPrimaryTopicOf
wikipedia-en:Symplocamide_A